Companies in #Metabolic Disease

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for obesity and metabolic disease, with a lead asset (ribupatide) targeting GLP-1/GIP dual agonism. The company completed a record-setting IPO in early June 2026 and presented positive Chinese Phase 2 data at the American Diabetes Association conference, positioning it as a notable China-originated obesity biotech in the public markets.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that developed and commercialized Rezdiffra (resmetirom), the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-severe liver fibrosis. The company is now pursuing expanded indications and next-generation oral small-molecule therapeutics for liver and metabolic diseases.

Sciwind Biosciences is a Chinese clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for metabolic disease, with a lead asset in obesity based on a once-monthly GLP-1/glucagon dual agonist formulation. The company has signed two Western licensing deals for its obesity candidate and is open to additional geographic partnerships as it seeks to expand beyond the Chinese market.